Active Ingredient History
Oleclumab is a human monoclonal antibody targeting the ectonucleotidase CD73 that was designed for the treatment of pancreatic and colorectal and other cancers. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Breast Neoplasms (Phase 2)
Carcinoma (Phase 1/Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 3)
Carcinoma, Renal Cell (Phase 2)
Liposarcoma (Phase 2)
Neoplasm Metastasis (Phase 2)
Neoplasms (Phase 1)
Osteosarcoma (Phase 2)
Ovarian Neoplasms (Phase 2)
Pancreatic Neoplasms (Phase 2)
Prostatic Neoplasms (Phase 2)
Sarcoma (Phase 2)
Sepsis (Phase 2)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Triple Negative Breast Neoplasms (Phase 1/Phase 2)
Urinary Bladder Neoplasms (Phase 1)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue